Loxenatide
Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia
Company n/r · Phase 2/3 · Completed · Enrollment 30
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| LNG-IUS | Obesity or overweight | n/r | n/r | n/r | n/r |
| LOX+LNG-IUS | Obesity or overweight | n/r | n/r | n/r | n/r |